Biogen Idec first one fourth revenues boost 9 percent to $1.

‘We continued our transformation right into a lean, focused and aggressive company, and the reinvigoration of Research and Advancement is underway well. We met several interesting pipeline milestones, like the positive Stage III data read-out from the DEFINE trial for BG-12, our oral MS drug applicant, and the enrollment of the 1st patient in our Stage III EMPOWER trial for dexpramipexole, a potential treatment for ALS. We continue steadily to unlock TYSABRI’s potential through leading edge science and are motivated by the CHMP’s positive opinion to add anti-JC virus antibody position as yet another risk element for PML in the TYSABRI label. With these successes, we anticipate continue steadily to drive our primary business and progress our deep late-stage pipeline.’ Talk about Repurchases Related StoriesOncolytic viral therapy accepted in the U.S.What we'escape that is a puzzle piece ll, a concept of a molecule that disrupts the hedgehogs without leading to undue side effects. The best candidates will be tested in laboratory animals, sometime in 2017 probably, Callahan says. From then on? It's a matter of where in fact the science leads. You want to reach molecularly targeted therapy, Callahan says. Essentially, a magic pill that kills the cancers rather than the patient.. Caltech chemists develop new sensitive technique that may detect colorectal tumor in tissue samples Chemists at Caltech have developed a fresh sensitive technique capable of detecting colorectal cancer in tissue samples – – a way that could one day be used in clinical configurations for the first diagnosis of colorectal cancers.